2013-2014

The Parliament of the Commonwealth of Australia

HOUSE OF REPRESENTATIVES/THE SENATE

#### **EXPOSURE DRAFT (16/01/2014)**

# **Intellectual Property Laws Amendment Bill 2014**

No. , 2014

(Industry)

A Bill for an Act to amend legislation relating to intellectual property, and for related purposes

#### **EXPOSURE DRAFT**

Contents		
1	Short title	1
2	Commencement	
3	Schedule(s)	3
Schedule 1—TR	IPS Protocol interim waiver	4
Part 1—Ame	endments	4
Patents Ac	ct 1990	4
Part 2—App	lication	21
Schedule 2—TR	AIPS Protocol: later commencing amendments	22
Patents Ac	ct 1990	22
Schedule 3—Pla	nt Breeder's Rights Act 1994: Federal Circuit	
Co	urt	23
Plant Bree	eder's Rights Act 1994	23
Schedule 4—Au	stralia New Zealand Single Economic Market	27
Part 1—Ame	endments	27
Designs A	act 2003	27
Patents Ac	ct 1990	27
Plant Bree	eder's Rights Act 1994	40
Trade Ma	rks Act 1995	42
Part 2—Tran	nsitional provisions	44
Schedule 5—Otl	her amendments	47
Part 1—Doc	ument retention	47
Division 1	1—Amendments	47
Designs A	act 2003	47
Patents Ac	ct 1990	47
Trade Ma	rks Act 1995	47
Division 2	2—Application of amendments	47
Part 2—Tech	nnical amendments	48
Division 1	I—Amendments	48

No. , 2014

Intellectual Property Laws Amendment Bill 2014

Patents Act 1990		48
Division 2—Appl	ication of amendments	50

Intellectual Property Laws Amendment Bill 2014

ii

intellectual p		_
The Parliame	ent of Australia enacts:	
1 Short title		
	Act may be cited as the <i>Intellectual Prope</i> dment Act 2014.	erty Laws
2 Commenceme	nt	
comm colum	provision of this Act specified in column ences, or is taken to have commenced, in a 2 of the table. Any other statement in colling to its terms.	accordance with
Commencement in		
Column 1	Column 2	Column 3
		Date/Details
Column 1 Provision(s)  1. Sections 1 to 3 and anything in this Act not elsewhere covered	Column 2 Commencement	Date/Details

Intellectual Property Laws Amendment Bill 2014

	information Column 2	Column 2
Column 1	Column 2	Column 3
Provision(s)	Commencement  Establishing the World Trade Organization, done at Marrakesh on 15 April 1994, comes into force for Australia.	Date/Details
	However, the provision(s) do not commence at all if the event mentioned in paragraph (b) does not occur.	
	The Minister administering the <i>Patents Act</i> 1990 must announce by notice in the Gazette the day the event mentioned in paragraph (b) occurs.	
4. Schedule 3	The day after the end of the period of 6 months beginning on the day this Act receives the Royal Assent.	
5. Schedule 4	A single day to be fixed by Proclamation.  However, if the provision(s) do not commence within the period of 24 months beginning on the day this Act receives the Royal Assent, the provision(s) are repealed on the day after the end of that period.	
6. Schedule 5, Part 1	The day after this Act receives the Royal Assent.	
7. Schedule 5, item 6	Immediately after the commencement of item 32 of Schedule 6 to the <i>Intellectual Property Laws Amendment (Raising the Bar) Act 2012.</i>	15 April 2013
8. Schedule 5, items 7 to 15	A single day to be fixed by Proclamation.  However, if the provision(s) do not commence within the period of 6 months beginning on the day this Act receives the Royal Assent, they commence on the day after the end of that period.	
9. Schedule 5, item 16	Immediately after the commencement of item 32 of Schedule 6 to the <i>Intellectual Property Laws Amendment (Raising the Bar) Act 2012</i> .	15 April 2013

Intellectual Property Laws Amendment Bill 2014 No. , 2014

Column 1	Column 2	Column 3	
Provision(s)	Commencement	Date/Details	
10. Schedule 5,	A single day to be fixed by Proclamation.		
items 17 to 19	However, if the provision(s) do not		
	commence within the period of 6 month	S	
	beginning on the day this Act receives the		
	Royal Assent, they commence on the da	y	
	after the end of that period.		
11. Schedule 5,	The day this Act receives the Royal Asse	ent.	
item 20			
Note	, <u>F</u>		
	enacted. It will not be amended to deal wit this Act.	h any later amendment	
(2) An	information in column 3 of the table is	not part of this Act	
	ormation may be inserted in this column,	_	
	be edited, in any published version of the		
3 Schedule(s)			
Eac	h Act that is specified in a Schedule to the	is Act is amended	
	ealed as set out in the applicable items in		
	cerned, and any other item in a Schedule		
	ording to its terms.		

Schedule 1 TRIPS Protocol interim waiver Part 1 Amendments

#### Schedule 1—TRIPS Protocol interim waiver

P	art 1—Amendments
P	atents Act 1990
1	Section 3 (list of definitions) Omit "compulsory licence".
2	Section 3 (list of definitions) Insert "eligible importing country".
3	Section 3 (list of definitions)  Insert "patented pharmaceutical invention".
4	Section 3 (list of definitions) Insert "pharmaceutical product".
5	Section 3 (list of definitions) Insert "PPI".
6	Section 3 (list of definitions) Insert "PPI compulsory licence".
7	Section 3 (list of definitions) Insert "PPI order".
8	Section 3 (list of definitions) Insert "PPI order applicant".
9	Section 3 (list of definitions) Insert "TRIPS Agreement".
1 (	0 Section 3 (list of definitions)

Intellectual Property Laws Amendment Bill 2014

Insert "WTO General Council decision of 30 August 2003".

23

TRIPS Protocol interim waiver **Schedule 1**Amendments **Part 1** 

1	11 Before subsection 70(5)
2	Insert:
3	Meaning of first regulatory approval date
4	12 After subsection 70(5)
5	Insert:
6 7 8 9 10	(5A) For the purposes of paragraph (5)(a), disregard an inclusion in the Australian Register of Therapeutic Goods of goods that contain, or consist of, a pharmaceutical substance if the inclusion was sought for the sole purpose of exporting the goods from Australia to address a public health problem in an eligible importing country:
11	(a) in circumstances of national emergency or other
12 13	circumstances of extreme urgency; or (b) by the public non-commercial use of the goods.
14 15	Note: This subsection also applies in relation to an application for an extension of the term of a standard patent (see paragraph 71(2)(b)).
16	Meaning of pre-TGA marketing approval
17	13 At the end of paragraph 71(2)(b)
18	Add ", as worked out under subsection 70(5A) (if applicable)".
19	14 Before section 133
20	Insert:
21 22	Part 1—Introduction
23	132A Simplified outline of this Chapter
24	This Chapter provides for court orders requiring the grant of
25	compulsory licences in respect of patented inventions.
26	Special provision is made for compulsory licences to exploit
27	patented pharmaceutical inventions. This is to enable the
28	manufacture of a pharmaceutical product in Australia for export to

No. , 2014

Intellectual Property Laws Amendment Bill 2014

Schedule 1 TRIPS Protocol interim waiver Part 1 Amendments

1 2		an eligible importing country, to address public health problems in that country.
3 4		This Chapter also provides generally for the surrender of patents, and for court orders revoking patents.
5 6	Part 2–	-Compulsory licences (general)
7	132B Sim	pplified outline of this Part
8		The Federal Court may make an order under this Part requiring the grant of a compulsory licence to work a patented invention.
10 11 12		The court may order a compulsory licence to be granted if the reasonable requirements of the public are not being met with respect to a patented invention.
13 14 15 16 17		The reasonable requirements of the public relate, broadly speaking, to whether Australian trade or industry is unreasonably affected by the actions of the patentee in relation to the manufacture or licensing of the invention (or the carrying on of a patented process).
18 19 20 21		The court may also order a compulsory licence to be granted if the patentee has engaged in restrictive trade practices in connection with the patent under the <i>Competition and Consumer Act 2010</i> or under an application law (within the meaning of that Act).
22 23 24		The court may order a patent to be revoked after an order for a compulsory licence has been made (on the same grounds that apply to an order for a compulsory licence).
25 26		The patentee must be paid an agreed amount of remuneration, or an amount of remuneration determined by the court.
27 28		on 133 (heading) peal the heading, substitute:

Intellectual Property Laws Amendment Bill 2014 No. , 2014

TRIPS Protocol interim waiver **Schedule 1**Amendments **Part 1** 

16 At t	he end c	of subsection 133(1)
A	Add:	
	Note:	For compulsory licences for the manufacture and export of patern pharmaceutical inventions to eligible importing countries, see Pa However, Part 3 does not prevent a compulsory licence from bei ordered under this Part in relation to such an invention (see section 136C).
17 Sec	tion 134	(heading)
F	Repeal the l	neading, substitute:
134 Re	vocation o	of patent after grant of compulsory licence under n 133
18 Suk	section	134(1)
A	After "com	pulsory licence", insert "ordered under section 133".
19 Afte	er sectio	n 136A
I	nsert:	
Part 3	—Pate	ented pharmaceutical invention
1 41 0		pulsory licences (for manufacture an
		`
	expo	ort to eligible importing countries)
Divisio	n 1—In	troduction
136B S	implified	outline of this Part
	The Fe	deral Court may make an order under this Part requiring
		of a compulsory licence to exploit a patented pharmaceut
		on for manufacture and export to an eligible importing

No. , 2014

Intellectual Property Laws Amendment Bill 2014

Schedule 1 TRIPS Protocol interim waiver Part 1 Amendments

1 2 3		proposed	t may order a compulsory licence to be granted if the use of the pharmaceutical product is to address a public sue in the eligible importing country:
4 5		(a)	in a national emergency (or other extremely urgent circumstances); or
6		(b)	by the public non-commercial use of the product.
7		The orde court.	r may be amended or revoked by another order of the
9 10			ntee must be paid an agreed amount of remuneration, or an of remuneration determined by the court.
11	136C Rela	ntionship	between Parts 2 and 3
12			does not prevent a compulsory licence from being
13 14		ordered u	under Part 2 in relation to a patented pharmaceutical
			-
15	Division		ented pharmaceutical invention
16		compu	llsory licences
	136D PPI	•	sory licences—applications for orders
16 17 18	136D PPI	compuls	·
17		Application A person for an order application apharma	sory licences—applications for orders
17 18 19 20 21 22 23 24 25 26 27		Application A person for an order application apharma	sory licences—applications for orders  ion for order  (the <i>PPI order applicant</i> ) may apply to the Federal Court der (the <i>PPI order</i> ) under section 136E requiring the of a patented pharmaceutical invention to grant the PPI plicant a licence (a <i>PPI compulsory licence</i> ) to exploit the into the extent necessary for the purposes of manufacturing incentical product in Australia for export to an eligible
117 118 119 220 221 222 223 224		Application A person for an order application applicat	sory licences—applications for orders  ion for order  (the <i>PPI order applicant</i> ) may apply to the Federal Court der (the <i>PPI order</i> ) under section 136E requiring the of a patented pharmaceutical invention to grant the PPI plicant a licence (a <i>PPI compulsory licence</i> ) to exploit the into the extent necessary for the purposes of manufacturing inceutical product in Australia for export to an eligible grountry.  A patented pharmaceutical invention may be a patented product or a patented process: see the definition of <i>patented pharmaceutical</i>

TRIPS Protocol interim waiver **Schedule 1**Amendments **Part 1** 

1	,	(2) However, a person cannot appry for an order in respect of an
2		innovation patent unless the patent has been certified.
3		Statement—eligible importing country
4	(	(3) An application must include a copy of a statement made by or on
5		behalf of, and with the authorisation of, the eligible importing
6		country to the effect that it will take reasonable measures within its
7		means, proportionate to its administrative capacities and to the risk
8		of trade diversion, to prevent re-exportation from its territory of a
9		pharmaceutical product imported into its territory in accordance with a PPI compulsory licence.
10		with a FFI compulsory needee.
11		Statement—importer
12	(	(4) If the pharmaceutical product is to be imported on behalf of, and
13		with the authorisation of, the eligible importing country, an
14		application must also include a copy of a statement made by the
15		importer to the effect that it will take reasonable measures within
16		its means to prevent the pharmaceutical product from being used
17		other than in accordance with a PPI compulsory licence.
18		Parties
19		(5) The following are parties to proceedings on an application under
20		this section:
21		(a) the PPI order applicant;
22		(b) the patentee;
23		(c) any person claiming an interest in the patent as exclusive
24		licensee or otherwise;
25		(d) at the option of the eligible importing country—that country.
26	136E P	PI compulsory licences—orders
27		(1) After hearing an application for a PPI order under section 136D,
28		the Federal Court may, subject to this Part, make the order sought
29		if the court is satisfied of all of the following matters:
30		(a) the application is made in good faith;
31		(b) the pharmaceutical product is to be imported:
32		(i) by the eligible importing country; or

No. , 2014

Intellectual Property Laws Amendment Bill 2014

Schedule 1 TRIPS Protocol interim waiver Part 1 Amendments

(c) the proposed use of the pharmaceutical product is to address a public health problem in the eligible importing country:  (i) in circumstances of national emergency or other circumstances of extreme urgency; or  (ii) in other circumstances—by the public non-commercial use of the pharmaceutical product;  (d) exploiting the patented pharmaceutical invention is necessary to enable the import and proposed use of the pharmaceutical product as mentioned in paragraphs (b) and (c);  (e) if subparagraph (c)(ii) applies:  (i) the PPI order applicant has given the patentee a notice in the approved form seeking from the patentee an authorisation to exploit the patented pharmaceutical invention for public non-commercial use; and  (ii) during the 30 days beginning when the notice was given, the PPI order applicant has tried, without success, to obtain such an authorisation from the patentee on reasonable terms and conditions;  (f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may:  (a) without limiting subsection 33(3A) of the Acts Interpretation Act 1901, prescribe different notification requirements for the	1 2	(ii) by a person (the <i>third party importer</i> ) on behalf of, and with the authorisation of, the eligible importing country
a public health problem in the eligible importing country:  (i) in circumstances of national emergency or other circumstances of extreme urgency; or  (ii) in other circumstances—by the public non-commercial use of the pharmaceutical product;  (d) exploiting the patented pharmaceutical invention is necessary to enable the import and proposed use of the pharmaceutical product as mentioned in paragraphs (b) and (c);  (e) if subparagraph (c)(ii) applies:  (i) the PPI order applicant has given the patentee a notice in the approved form seeking from the patentee an authorisation to exploit the patented pharmaceutical invention for public non-commercial use; and  (ii) during the 30 days beginning when the notice was given, the PPI order applicant has tried, without success, to obtain such an authorisation from the patentee on reasonable terms and conditions;  (f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.	3	
circumstances of extreme urgency; or  (ii) in other circumstances—by the public non-commercial use of the pharmaceutical product;  (d) exploiting the patented pharmaceutical invention is necessary to enable the import and proposed use of the pharmaceutical product as mentioned in paragraphs (b) and (c);  (e) if subparagraph (c)(ii) applies:  (i) the PPI order applicant has given the patentee a notice in the approved form seeking from the patentee an authorisation to exploit the patented pharmaceutical invention for public non-commercial use; and  (ii) during the 30 days beginning when the notice was given, the PPI order applicant has tried, without success, to obtain such an authorisation from the patentee on reasonable terms and conditions;  (f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.		
circumstances of extreme urgency; or  (ii) in other circumstances—by the public non-commercial use of the pharmaceutical product;  (d) exploiting the patented pharmaceutical invention is necessary to enable the import and proposed use of the pharmaceutical product as mentioned in paragraphs (b) and (c);  (e) if subparagraph (c)(ii) applies:  (i) the PPI order applicant has given the patentee a notice in the approved form seeking from the patentee an authorisation to exploit the patented pharmaceutical invention for public non-commercial use; and  (ii) during the 30 days beginning when the notice was given, the PPI order applicant has tried, without success, to obtain such an authorisation from the patentee on reasonable terms and conditions;  (f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.	5	(i) in circumstances of national emergency or other
use of the pharmaceutical product;  (d) exploiting the patented pharmaceutical invention is necessary to enable the import and proposed use of the pharmaceutical product as mentioned in paragraphs (b) and (c);  (e) if subparagraph (c)(ii) applies:  (i) the PPI order applicant has given the patentee a notice in the approved form seeking from the patentee an authorisation to exploit the patented pharmaceutical invention for public non-commercial use; and  (ii) during the 30 days beginning when the notice was given, the PPI order applicant has tried, without success, to obtain such an authorisation from the patentee on reasonable terms and conditions;  (f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with, there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.	6	
(d) exploiting the patented pharmaceutical invention is necessary to enable the import and proposed use of the pharmaceutical product as mentioned in paragraphs (b) and (c);  (e) if subparagraph (c)(ii) applies:  (i) the PPI order applicant has given the patentee a notice in the approved form seeking from the patentee an authorisation to exploit the patented pharmaceutical invention for public non-commercial use; and  (ii) during the 30 days beginning when the notice was given, the PPI order applicant has tried, without success, to obtain such an authorisation from the patentee on reasonable terms and conditions;  (f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.	7	(ii) in other circumstances—by the public non-commercial
to enable the import and proposed use of the pharmaceutical product as mentioned in paragraphs (b) and (c);  (e) if subparagraph (c)(ii) applies:  (i) the PPI order applicant has given the patentee a notice in the approved form seeking from the patentee an authorisation to exploit the patentee pharmaceutical invention for public non-commercial use; and  (ii) during the 30 days beginning when the notice was given, the PPI order applicant has tried, without success, to obtain such an authorisation from the patentee on reasonable terms and conditions;  (f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.	8	use of the pharmaceutical product;
product as mentioned in paragraphs (b) and (c);  (e) if subparagraph (c)(ii) applies:  (i) the PPI order applicant has given the patentee a notice in the approved form seeking from the patentee an authorisation to exploit the patented pharmaceutical invention for public non-commercial use; and  (ii) during the 30 days beginning when the notice was given, the PPI order applicant has tried, without success, to obtain such an authorisation from the patentee on reasonable terms and conditions;  (f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.	9	(d) exploiting the patented pharmaceutical invention is necessary
(e) if subparagraph (c)(ii) applies:  (i) the PPI order applicant has given the patentee a notice in the approved form seeking from the patentee an authorisation to exploit the patented pharmaceutical invention for public non-commercial use; and  (ii) during the 30 days beginning when the notice was given, the PPI order applicant has tried, without success, to obtain such an authorisation from the patentee on reasonable terms and conditions;  (f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may:  (a) without limiting subsection 33(3A) of the Acts Interpretation	10	
(i) the PPI order applicant has given the patentee a notice in the approved form seeking from the patentee an authorisation to exploit the patented pharmaceutical invention for public non-commercial use; and (ii) during the 30 days beginning when the notice was given, the PPI order applicant has tried, without success, to obtain such an authorisation from the patentee on reasonable terms and conditions; (f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with; (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may: (a) without limiting subsection 33(3A) of the Acts Interpretation	11	product as mentioned in paragraphs (b) and (c);
in the approved form seeking from the patentee an authorisation to exploit the patented pharmaceutical invention for public non-commercial use; and  (ii) during the 30 days beginning when the notice was given, the PPI order applicant has tried, without success, to obtain such an authorisation from the patentee on reasonable terms and conditions;  (f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may:  (a) without limiting subsection 33(3A) of the Acts Interpretation	12	(e) if subparagraph (c)(ii) applies:
authorisation to exploit the patented pharmaceutical invention for public non-commercial use; and  (ii) during the 30 days beginning when the notice was given, the PPI order applicant has tried, without success, to obtain such an authorisation from the patentee on reasonable terms and conditions;  (f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may:  (a) without limiting subsection 33(3A) of the Acts Interpretation	13	(i) the PPI order applicant has given the patentee a notice
invention for public non-commercial use; and  (ii) during the 30 days beginning when the notice was given, the PPI order applicant has tried, without success, to obtain such an authorisation from the patentee on reasonable terms and conditions;  (f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may:  (a) without limiting subsection 33(3A) of the Acts Interpretation	14	
(ii) during the 30 days beginning when the notice was given, the PPI order applicant has tried, without success, to obtain such an authorisation from the patentee on reasonable terms and conditions;  (f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may:  (a) without limiting subsection 33(3A) of the Acts Interpretation	15	
given, the PPI order applicant has tried, without success, to obtain such an authorisation from the patentee on reasonable terms and conditions;  (f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may:  (a) without limiting subsection 33(3A) of the Acts Interpretation	16	•
to obtain such an authorisation from the patentee on reasonable terms and conditions;  (f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may:  (a) without limiting subsection 33(3A) of the Acts Interpretation	17	
reasonable terms and conditions;  (f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may:  (a) without limiting subsection 33(3A) of the Acts Interpretation	18	
(f) the notification requirements prescribed by regulation in relation to the importation of the pharmaceutical product into the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may:  (a) without limiting subsection 33(3A) of the Acts Interpretation		
relation to the importation of the pharmaceutical product into the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may: (a) without limiting subsection 33(3A) of the Acts Interpretation		•
the eligible importing country have been complied with;  (g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may: (a) without limiting subsection 33(3A) of the Acts Interpretation		
(g) the PPI order applicant, the eligible importing country and, if there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may: (a) without limiting subsection 33(3A) of the Acts Interpretation		
there is a third party importer, that importer, will take reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may: (a) without limiting subsection 33(3A) of the Acts Interpretation		
reasonable measures to prevent a pharmaceutical product that is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may: (a) without limiting subsection 33(3A) of the Acts Interpretation		
is exported from Australia in accordance with a PPI compulsory licence from being used for a purpose other than the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may: (a) without limiting subsection 33(3A) of the Acts Interpretation		A 7 A
the purpose of addressing the public health problem mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may: (a) without limiting subsection 33(3A) of the Acts Interpretation		
mentioned in paragraph (c).  (2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may:  (a) without limiting subsection 33(3A) of the Acts Interpretation	28	compulsory licence from being used for a purpose other than
(2) Without limiting the matters that the court may take into account in deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may:  (a) without limiting subsection 33(3A) of the <i>Acts Interpretation</i>	29	the purpose of addressing the public health problem
deciding whether it is satisfied of a matter mentioned in subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may:  (a) without limiting subsection 33(3A) of the <i>Acts Interpretation</i>	30	mentioned in paragraph (c).
subsection (1), the court must take into account any matters prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may:  (a) without limiting subsection 33(3A) of the <i>Acts Interpretation</i>	31	(2) Without limiting the matters that the court may take into account in
prescribed by regulation.  (3) A regulation made for the purposes of paragraph (1)(f) may:  (a) without limiting subsection 33(3A) of the <i>Acts Interpretation</i>	32	deciding whether it is satisfied of a matter mentioned in
(3) A regulation made for the purposes of paragraph (1)(f) may: (a) without limiting subsection 33(3A) of the <i>Acts Interpretation</i>	33	subsection (1), the court must take into account any matters
(a) without limiting subsection 33(3A) of the <i>Acts Interpretation</i>	34	prescribed by regulation.
(a) without limiting subsection 33(3A) of the <i>Acts Interpretation</i>	35	(3) A regulation made for the purposes of paragraph (1)(f) may:
	36	(a) without limiting subsection 33(3A) of the Acts Interpretation
	37	

TRIPS Protocol interim waiver **Schedule 1**Amendments **Part 1** 

1 2	importation of pharmaceutical products in importing countries of different kinds; and	
3	(b) despite subsection 14(2) of the <i>Legislative</i>	
4	2003, refer to eligible importing countries	
5	of eligible importing countries) by applying	
6	incorporating, with or without modificatio	
7	contained in any other instrument or other	-
8	or existing from time to time.	C
9	136F PPI compulsory licences—terms	
10	(1) A PPI order must direct that the PPI compulsory	licence is granted
11	on the following terms:	
12	(a) no more than the quantity of the pharmace	
13 14	is determined by the Federal Court to be n the needs of the eligible importing country	•
15	(b) the entirety of the pharmaceutical product	manufactured for
16	that purpose is exported to that country;	
17	(c) the pharmaceutical product is labelled and	marked in
18	accordance with the regulations;	
19	(d) before shipment of the pharmaceutical pro	
20	shipment information prescribed by regula	
21	available on a website by, or on behalf of,	
22	minimum period prescribed by regulation;	
23	(e) the duration of the licence is only for the p	
24	determined by the Federal Court to be nec	essary to address
25	the public health problem concerned;	
26	(f) the licence does not give the licensee, or a	
27	by the licensee, the exclusive right to expl	oit the patented
28	pharmaceutical invention;	
29	(g) the licence is to be assignable only in conr	
30	enterprise or goodwill in connection with	which the licence is
31	used;	
32	(h) the licensee must give the Commissioner t	
33	prescribed by regulation in relation to the	licence in
34	accordance with the regulations.	
35	(2) A PPI order may also direct that the licence is to	be granted on any
36	other terms specified in the order, including term	
	_	-

No. , 2014

Intellectual Property Laws Amendment Bill 2014

**Schedule 1** TRIPS Protocol interim waiver **Part 1** Amendments

1 2 3 4	<ul><li>(a) other requirements relating to the labelling and marking of the pharmaceutical product; and</li><li>(b) other information to be made available by the licensee and the way in which it is to be made available.</li></ul>
5 (3) 6 7	However, a term specified in a PPI order must not be inconsistent with any regulations prescribed for the purposes of paragraph (1)(c), (d) or (h).
8 136G PPI	compulsory licences—amendment
9	Application for order
10 (1) 11 12 13	A person may apply to the Federal Court for an order amending any of the following terms of a PPI compulsory licence:  (a) the quantity of the pharmaceutical product concerned;  (b) how the pharmaceutical product is labelled and marked;  (c) the duration of the licence;
15 16	(d) the information that is to be made available by the licensee and the way it is to be made available.
17 18	Note: For remuneration in respect of the licence as amended, see section 136J.
19	Order
20 (2) 21 22 23 24 25 26 27 28	The court may make the order sought in relation to a term if it is satisfied that:  (a) it is just to do so in all the circumstances; and  (b) the legitimate interests of the following are not likely to be adversely affected by the amendment of the term:  (i) the patentee;  (ii) any person claiming an interest in the patent as exclusive licensee or otherwise;  (iii) the licensee;
29	(iv) the eligible importing country.
30 (3) 31 32	However, an amended term must not be inconsistent with any regulations prescribed for the purposes of paragraph 136F(1)(c), (d) or (h).

Intellectual Property Laws Amendment Bill 2014

12

TRIPS Protocol interim waiver **Schedule 1**Amendments **Part 1** 

1	Parties
2	(4) The following are parties to any proceedings under this section:
3	(a) the applicant under subsection (1);
4	(b) the patentee;
5	(c) any person claiming an interest in the patent as exclusive
6	licensee or otherwise;
7	(d) the licensee;
8	(e) at the option of the eligible importing country—that country.
9	136H PPI compulsory licences—revocation
10	Application
11 12	(1) A person may apply to the Federal Court for an order revoking a PPI compulsory licence.
13 14	Note: For remuneration in respect of the use of a PPI compulsory licence while it is in force, see section 136J.
15	Federal Court may revoke licence
16 17	(2) The Federal Court may make the order sought if the court is satisfied that:
18	(a) one or more of the following applies:
19	(i) the substantive circumstances that justified the grant of
20	the licence have ceased to exist and are unlikely to
21	recur;
22 23	(ii) the licensee has not complied with the terms of the licence;
24	(iii) if an amount of remuneration has been agreed or
25	determined under section 136J—the amount has not
26	been paid within the time agreed or determined; and
27	(b) the legitimate interests of the licensee or the eligible
28	importing country are not likely to be adversely affected by
29	the revocation.
30	Parties
31 32	<ul><li>(3) The following are parties to any proceedings under this section:</li><li>(a) the applicant for revocation;</li></ul>

No. , 2014

Intellectual Property Laws Amendment Bill 2014

**Schedule 1** TRIPS Protocol interim waiver **Part 1** Amendments

—Remuneration  mpulsory licences—remuneration  Torking out amount of remuneration
mpulsory licences—remuneration  Torking out amount of remuneration
Torking out amount of remuneration
the patentee is to be paid an amount agreed or determined under absection (3) in respect of the use of a patented pharmaceutical vention authorised by a PPI compulsory licence.
or the purposes of subsection (1), the use of a patented narmaceutical invention authorised by the PPI compulsory licence
(a) while it is in force—the use authorised by the licence as granted and as amended (from time to time) under section 136G; or
(b) if it has ceased to be in force (whether because it was revoked or otherwise)—the actual use of the patented pharmaceutical invention under the licence while it was in force.
or the purposes of subsection (1), the amount is:
(a) an amount agreed between the patentee and the PPI order applicant, licensee or former licensee (as the case requires); or
(b) if paragraph (a) does not apply—an amount determined by the Federal Court to be adequate remuneration taking into account the economic value to the eligible importing country of the use of the patented pharmaceutical invention
authorised by the PPI compulsory licence.
oplication to make or amend a determination
person may apply to the Federal Court:
<ul><li>(a) to make a determination under paragraph (3)(b); or</li><li>(b) to amend a determination made under that paragraph.</li></ul>
(

TRIPS Protocol interim waiver **Schedule 1**Amendments **Part 1** 

1 2 3	Note: Grounds for an application under paragraph (b) may include the fact that the terms of the PPI compulsory licence have been amended, or the licence has been revoked.
4	Parties
5	(5) The following are parties to any proceedings under this section:
6	(a) the applicant for the determination or the amendment of the
7	determination;
8	(b) the PPI order applicant;
9	(c) the licensee;
10	(d) the patentee of the patented pharmaceutical invention;
11	(e) any person claiming an interest in the patent as exclusive
12	licensee or otherwise.
13	Can PPI be exploited if remuneration is not agreed or determined?
14	(6) To avoid doubt, if the proposed use of the pharmaceutical product
15	is to address a public health problem in the eligible importing
16	country in circumstances of national emergency or other
17	circumstances of extreme urgency, the licensee may exploit a
18	patented pharmaceutical invention under a PPI compulsory licence,
19 20	as granted or amended (as the case may be), whether or not an amount has been agreed or determined under this section.
20	amount has been agreed of determined under this section.
21	(7) However, if the proposed use of the pharmaceutical product is to
22	address a public health problem in the eligible importing country in
23	other circumstances, by the public non-commercial use of the
24 25	pharmaceutical product, the licensee must not exploit a patented pharmaceutical invention under a PPI compulsory licence unless an
25 26	amount has been agreed or determined under this section.
	uniouni nuo coon ugi oco oi ucominiou uniori unio socioni
27	Can PPI compulsory licence be revoked if remuneration is not
28	agreed or determined?
29	(8) To avoid doubt, a PPI compulsory licence may be revoked whether
30	or not an amount has been agreed or determined under this section.

**Schedule 1** TRIPS Protocol interim waiver **Part 1** Amendments

Divis	ion 4—General
136K	PPI compulsory licences—nature of orders
	Without prejudice to any other method of enforcement, a PPI order operates as if it were embodied in a deed granting or amending a licence and executed by the patentee and all other necessary parties.
136L	PPI compulsory licences—consistency of orders with international agreements
	A PPI order must not be made that is inconsistent with a treaty between the Commonwealth and a foreign country.
136M	PPI compulsory licences—applications heard together
Part	Nothing in this Part prevents the Federal Court from dealing with the following applications together:  (a) applications for different PPI orders, or for the amendment or revocation of such orders;  (b) applications for determinations under paragraph 136J(3)(b) for remuneration in relation to different PPI compulsory licences, or for the amendment of such determinations.  4—Surrender and revocation of patents  Simplified outline of this Part
	A patentee may offer to surrender a patent by giving the Commissioner written notice.
	The Commissioner may accept the offer of surrender, and revoke the patent, after hearing all interested parties. If court proceedings are pending in relation to the patent, leave of the court, or the consent of the parties, is required. The Commissioner must not accept the offer if a compulsory licence is in force in relation to the

Intellectual Property Laws Amendment Bill 2014

TRIPS Protocol interim waiver **Schedule 1**Amendments **Part 1** 

	In addition, a court may revoke a patent on the following grounds:	
	(a) the patentee is not entitled to the patent;	
	(b) the invention is not a patentable invention;	
	(c) the patent was (broadly speaking) improperly obtained;	
	(d) the patent was (broadly speaking) obtained on the basis of a non-compliant specification.	
20 Subs	section 137(5)	
On	nit "compulsory licence", substitute "licence ordered under Part 2".	
21 After	section 138	
Ins	ert:	
Dart 5	—Other matters	
rait 5–	—Other matters	
138A Sin	aplified outline of this Part	
138A Sin	nplified outline of this Part	_
38A Sin	This Part deals with the parties to proceedings under this Chapter (other than proceedings under Part 3).	
38A Sin	This Part deals with the parties to proceedings under this Chapter	
	This Part deals with the parties to proceedings under this Chapter (other than proceedings under Part 3).  This Part also enables the Commissioner to appear and be heard in all proceedings under this Chapter.	_
	This Part deals with the parties to proceedings under this Chapter (other than proceedings under Part 3).  This Part also enables the Commissioner to appear and be heard in all proceedings under this Chapter.  e end of subsection 139(1)	
22 At the	This Part deals with the parties to proceedings under this Chapter (other than proceedings under Part 3).  This Part also enables the Commissioner to appear and be heard in all proceedings under this Chapter.  e end of subsection 139(1)	
<b>22 At th</b> e Ad	This Part deals with the parties to proceedings under this Chapter (other than proceedings under Part 3).  This Part also enables the Commissioner to appear and be heard in all proceedings under this Chapter.  e end of subsection 139(1)	
22 At the Ad 23 Subs	This Part deals with the parties to proceedings under this Chapter (other than proceedings under Part 3).  This Part also enables the Commissioner to appear and be heard in all proceedings under this Chapter.  e end of subsection 139(1) d:  Note: See Part 3 for details of parties to proceedings under that Part.	
22 At the Ad  23 Subs	This Part deals with the parties to proceedings under this Chapter (other than proceedings under Part 3).  This Part also enables the Commissioner to appear and be heard in all proceedings under this Chapter.  e end of subsection 139(1)  d:  Note: See Part 3 for details of parties to proceedings under that Part.  section 139(2)  nit "section 133, 134 or 138", substitute "this Chapter".	
22 At the Ad  23 Subs	This Part deals with the parties to proceedings under this Chapter (other than proceedings under Part 3).  This Part also enables the Commissioner to appear and be heard in all proceedings under this Chapter.  e end of subsection 139(1)  d:  Note: See Part 3 for details of parties to proceedings under that Part.  section 139(2)  nit "section 133, 134 or 138", substitute "this Chapter".  e end of subsection 228(1)	

Intellectual Property Laws Amendment Bill 2014

17

**Schedule 1** TRIPS Protocol interim waiver **Part 1** Amendments

18

25	After subsec	tion 228(4)
	Insert:	
	(5) Despite	subsection 14(2) of the Legislative Instruments Act 2003,
	•	ons made for the purposes of the definition of <i>eligible</i>
	_	eg country in Schedule 1 may make provision in relation to
		by applying, adopting or incorporating, with or without ation, any matter contained in any other instrument or other
		as in force or existing from time to time.
26	Schedule 1 (d	definition of compulsory licence)
	Repeal the de	finition.
27	Schedule 1	
	Insert:	
		<i>importing country</i> means a foreign country of a kind ed by regulation.
	Note:	A regulation made for the purposes of this definition may make
		provision in relation to a matter by applying, adopting or incorporating, with or without modification, any matter contained in
		any other instrument or other writing as in force or existing from time to time (see subsection 228(5)).
28	Schedule 1	
	Insert:	
	<del>-</del>	pharmaceutical invention, in relation to a pharmaceutical
	product,	
		the product is a patented product—the patented product; or
		the product results from the use of a patented process—the tented process.
00	•	process.
29	Schedule 1	
	Insert:	
		ceutical product means any patented product, or product
		tured through a patented process, of the pharmaceutical
	sector.	
	Example:	Examples of a pharmaceutical product include:

Intellectual Property Laws Amendment Bill 2014

TRIPS Protocol interim waiver **Schedule 1**Amendments **Part 1** 

	(a) active ingredients necessary for manufacturing such a production and
	(b) diagnostic kits needed for using such a product.
30	Schedule 1
	Insert:
	<b>PPI</b> is short for patented pharmaceutical invention.
31	Schedule 1
	Insert:
	PPI compulsory licence has the meaning given by section 136.
32	Schedule 1
	Insert:
	<b>PPI order</b> has the meaning given by section 136D.
33	Schedule 1
	Insert:
	<b>PPI order applicant</b> has the meaning given by section 136D.
34	Schedule 1
	Insert:
	TRIPS Agreement means the Agreement on Trade-Related
	Aspects of Intellectual Property Rights set out in Annex 1C to
	Marrakesh Agreement establishing the World Trade Organizati done at Marrakesh on 15 April 1994, as Annex 1C is in force for
	Australia from time to time.
	Note: The WTO Agreement is in Australian Treaty Series 1995 No. 8
	([1995] ATS 8) and could in 2014 be viewed in the Australian Treaties Library on the AustLII website (http://www.austlii.edu.au
35	Schedule 1
	Insert:
	WTO General Council decision of 30 August 2003 means the
	decision of the World Trade Organization General Council of

Intellectual Property Laws Amendment Bill 2014

19

**Schedule 1** TRIPS Protocol interim waiver **Part 1** Amendments

	30 Aug	gust 2003 (including the Annex to the decision) on the
2	implen	nentation of paragraph 6 of the Doha Declaration on the
3	TRIPS	Agreement and public health.
ļ ī	Note:	The decision could in 2014 be viewed on the World Trade Organization website (http://www.wto.org).

Intellectual Property Laws Amendment Bill 2014

TRIPS Protocol interim waiver **Schedule 1**Application **Part 2** 

#### Part 2—Application

3

4

5

#### 2 36 Application of amendments

- (1) The amendments of the *Patents Act 1990* made by this Schedule apply in relation to patents granted before, on and after the commencement of this Schedule.
- The amendments of sections 70 and 71 of the *Patents Act 1990* made by this Schedule apply in relation to an application that is made on or after the commencement of this Schedule to include a pharmaceutical substance in the Australian Register of Therapeutic Goods.

No. , 2014

Intellectual Property Laws Amendment Bill 2014

Schedule 2 TRIPS Protocol: later commencing amendments

1 2 3	Schedule 2—TRIPS Protocol: later commencing amendments
4	Patents Act 1990
5	1 Section 3 (list of definitions)
6	Omit "WTO General Council decision of 30 August 2003".
7	2 Paragraph 228(1)(f)
8 9	Omit "WTO General Council decision of 30 August 2003", substitute "TRIPS Agreement".
10 11	3 Schedule 1 (definition of WTO General Council decision of 30 August 2003)
12	Repeal the definition.

Plant Breeder's Rights Act 1994: Federal Circuit Court Schedule 3

•	Federal Circuit Court
P	lant Breeder's Rights Act 1994
1	Subsection 3(1) (definition of <i>Court</i> )  Repeal the definition.
2	Subsection 3(1) Insert:
	<i>Federal Circuit Court</i> means the Federal Circuit Court of Australia.
3	Subsection 3(1)
	Insert:
	Federal Court means the Federal Court of Australia.
4	Subsection 39(5)
	Repeal the subsection, substitute:
	(5) Nothing in this section affects the power of:
	(a) the Federal Court, or a Judge of that Court, under subsection 44A(2) of the AAT Act; or
	(b) the Federal Circuit Court, or a Judge of that Court, under subsection 44A(2A) of that Act;
	where an appeal is begun in that court from a decision of the AA
5	Subsection 50(7)
	Repeal the subsection, substitute:
	(7) Nothing in this section affects the power of:
	(a) the Federal Court, or a Judge of that Court, under
	subsection 44A(2) of the AAT Act; or  (b) the Federal Circuit Court, or a Judge of that Court, under
	(b) the Federal Circuit Court, or a Judge of that Court, under subsection 44A(2A) of that Act.

No. , 2014

Intellectual Property Laws Amendment Bill 2014

**Schedule 3** Plant Breeder's Rights Act 1994: Federal Circuit Court

1 2	<b>6 Subsection 54(1)</b> Omit "Court", substitute "Federal Court or the Federal Circuit Court".
3	7 Subsections 54(3) and (4) Omit "Court" (wherever occurring), substitute "court".
5 6	8 Subsection 55(1) Omit "Court", substitute "Federal Court or the Federal Circuit Court".
7	9 Subsections 55(3) and (4) Omit "Court", substitute "court".
9 10	10 Section 56 (heading) Repeal the heading, substitute:
11	56 Jurisdiction of the Federal Court
12 13	11 Subsection 56(1) Omit "Court" (wherever occurring), substitute "Federal Court".
14 15 16	12 At the end of subsection 56(1) Add:  Note: A matter may also be transferred to the Federal Court from the Federal
17 18	Circuit Court: see section 39 of the Federal Circuit Court of Australia Act 1999.
19	13 Subsection 56(2)
20	Repeal the subsection, substitute:
21 22	(2) That jurisdiction is exclusive of the jurisdiction of all other courts other than the jurisdiction of:
23 24	<ul><li>(a) the Federal Circuit Court under subsection 56A(2); and</li><li>(b) the High Court under section 75 of the Constitution.</li></ul>
25	14 Subsection 56(3)
26	Omit "Court" (wherever occurring), substitute "Federal Court".

Intellectual Property Laws Amendment Bill 2014

24

Plant Breeder's Rights Act 1994: Federal Circuit Court Schedule 3

2	15 5	Omit "Court", substitute "Federal Court".
3	16 S	ubsection 56(5)
4		Omit "the Court", substitute "the Federal Court".
5	17 S	ubsection 56(5)
6		Omit "rules", substitute "Rules".
7	Note:	This item fixes a typographical error.
8	18 A	fter section 56
9		Insert:
10	56A .	Jurisdiction of Federal Circuit Court
11 12 13		(1) The Federal Circuit Court has jurisdiction with respect to matters in which actions may, under this Part, be begun in the Federal Circuit Court.
14 15 16		Note: A matter may also be transferred to the Federal Circuit Court from the Federal Court: see section 32AB of the <i>Federal Court of Australia Act 1976</i> .
17 18		(2) That jurisdiction is exclusive of the jurisdiction of all other courts, other than the jurisdiction of:
19 20		<ul><li>(a) the Federal Court under subsection 56(2) of this Act; and</li><li>(b) the High Court under section 75 of the Constitution.</li></ul>
21 22		(3) The relief that the Federal Circuit Court may grant in an action or proceeding for infringement of PBR includes an injunction (subjec
22 23 24		to such terms, if any, as the Federal Circuit Court thinks fit) and, at the option of the plaintiff, either damages or an account of profits.
25		(4) The regulations may make provision in relation to the practice and
26		procedure of the Federal Circuit Court in actions under this Act,
27		including provision prescribing the time within which any action
28 29		may be begun, or any other act or thing may be done, and providing for the extension of any such time.
30 31		(5) Subsection (4) does not limit the power of the Judges of the Federal Circuit Court, or a majority of them, to make Rules of

No. , 2014

Intellectual Property Laws Amendment Bill 2014

**Schedule 3** Plant Breeder's Rights Act 1994: Federal Circuit Court

1 2 3		Court under section 81 of the <i>Federal Circuit Court of Australia</i> Act 1999 that are consistent with the regulations referred to in that subsection.
4 5	19	Subsection 57(1) Omit "The Court", substitute "A court".
6 7	20	Subsection 57(1) Omit "the Court", substitute "the court".
8	21	Section 72
9 10 11		Omit "the High Court Rules and the Federal Court Rules", substitute "Rules of Court of the High Court, the Federal Court or the Federal Circuit Court".

Intellectual Property Laws Amendment Bill 2014

Australia New Zealand Single Economic Market Schedule 4
Amendments Part 1

Schedule 4—Australia New Zealand Single Economic Market
Part 1—Amendments
Designs Act 2003
1 Section 145 Before "Where", insert "(1)".
2 Section 145 After "Australia", insert "or New Zealand".
3 Section 145 Omit "post", substitute "a prescribed means".
<ul> <li>4 At the end of section 145</li> <li>Add:</li> <li>(2) After the time specified in the regulations, a reference in this</li> </ul>
section to an <i>address</i> includes a reference to an electronic address.  (3) The time specified under subsection (2) must be later than the day on which the regulations are registered under the <i>Legislative Instruments Act</i> 2003.
(4) For the purposes of this section, the question of whether an electronic address is in Australia is to be determined in accordance with the regulations.
(5) For the purposes of this section, the question of whether an electronic address is in New Zealand is to be determined in accordance with the regulations.
Patents Act 1990
5 Section 3 (list of definitions) Insert "Board".

No. , 2014

Intellectual Property Laws Amendment Bill 2014

**Schedule 4** Australia New Zealand Single Economic Market **Part 1** Amendments

1 2	6 Section 3 (list of definitions)  Insert "Director-General of IP Australia".
3	7 Section 3 (list of definitions)  Insert "New Zealand Assistant Commissioner of Patents".
5	8 Section 3 (list of definitions)  Insert "New Zealand Commissioner of Patents".
7 8	9 Section 3 (list of definitions) Insert "New Zealand delegate".
9 10	10 Section 3 (list of definitions) Insert "New Zealand Patents Minister".
11 12	11 Section 3 (list of definitions) Insert "New Zealand patents official".
13 14	12 Section 3 (list of definitions) Omit "Professional Standards Board".
15 16	13 Section 3 (list of definitions)  Insert "Registrar of Companies of New Zealand".
17 18 19	14 Subsection 20(2)  Omit "or an employee,", substitute "an employee, or a New Zealand delegate,".
20 21	15 At the end of section 20 Add:
22 23	(3) For the purposes of this section, it is immaterial whether an act was done in New Zealand.
24 25	16 At the end of section 183 Add:

Australia New Zealand Single Economic Market Schedule 4
Amendments Part 1

1		(3) The Designated Manager may disclose to the Registrar of
2		Companies of New Zealand information (including personal
3		information within the meaning of the <i>Privacy Act 1988</i> ) that is:
4		(a) relevant to the functions conferred on the Registrar of
5		Companies of New Zealand by or under the Companies Act 1993 of New Zealand; and
6		,
7		(b) obtained by the Designated Manager as a result of the performance of functions and duties, or the exercise of
8 9		powers, in relation to incorporated patent attorneys.
9		powers, in relation to incorporated patent attorneys.
10		(4) For the purposes of subsection (3), it is immaterial whether the
11		disclosure takes place in New Zealand.
12		(5) The Commissioner may disclose to a New Zealand delegate
13		information (including personal information within the meaning of
14		the <i>Privacy Act 1988</i> ) that is relevant to the exercise of the powers,
15		or the performance of the functions, delegated to the New Zealand
16		delegate under subsection 209(1A).
17		(6) For the purposes of subsection (5), it is immaterial whether the
18		disclosure takes place in New Zealand.
19	17 Se	ction 185
20		Repeal the section.
21	18 Pa	ragraph 198(4)(a)
22		Repeal the paragraph.
23	19 Su	bsection 198(5)
24		Omit "Professional Standards Board", substitute "Board".
2-7		Office Professional Standards Board , Substitute Board .
25	20 Su	bsections 198(7) and (8)
26		Repeal the subsections, substitute:
27		(7) A reference in this section to <i>conviction</i> of an offence includes a
28		reference to:
29		(a) the making of an order under section 19B of the Crimes Act
30		1914 in relation to the offence; or
31		(b) the making of an order under a corresponding provision of a
32		law of:

No. , 2014

Intellectual Property Laws Amendment Bill 2014

**Schedule 4** Australia New Zealand Single Economic Market **Part 1** Amendments

(i) a State; or
(ii) a Territory; or
(iii) New Zealand;
in relation to the offence.
At the end of section 198
Add:
New Zealand
(12) It is immaterial whether a matter mentioned in:
(a) paragraph (4)(b), (c), (d), (e), (f) or (g); or
(b) subsection (5); or
(c) paragraph (9)(a), (b) or (c); or
(d) paragraph (11)(b);
concerns something that happened in New Zealand.
Section 199
Before "The name", insert "(1)".
At the end of section 199
Add:
(2) It is immaterial whether the prescribed grounds concern something that happened in New Zealand.
Before subsection 209(1)
Insert:
Delegation to employees
After subsection 209(1)
Insert:
Delegation to New Zealand patents officials
(1A) The Commissioner may, by instrument, signed by him or her,

Intellectual Property Laws Amendment Bill 2014

30

Australia New Zealand Single Economic Market Schedule 4
Amendments Part 1

2		performed or exercised by the delegate in New Zealand.
3	26	Before subsection 209(2)
4		Insert:
5		Direction or supervision
6	27	Section 214
7		Before "A document", insert "(1)".
8	28	At the end of section 214
9		Add:
10 11 12		(2) For the purposes of this Act, a prescribed document is taken to have been filed with the Patent Office if the document is delivered or given to:
13		(a) the New Zealand Commissioner of Patents; or
14		(b) a New Zealand Assistant Commissioner of Patents; or
15 16		<ul><li>(c) a person who, under a law of New Zealand, is a delegate of the New Zealand Commissioner of Patents;</li></ul>
17		in a prescribed manner.
18 19 20		(3) The regulations may provide that a document filed with the Patent Office because of subsection (2) is taken to have been so filed at the time ascertained in accordance with the regulations.
21	29	Section 221
22		Before "Where", insert "(1)".
23	30	Section 221
24		After "Australia", insert "or New Zealand".
25	31	Section 221
26		Omit "post", substitute "a prescribed means".
27	32	At the end of section 221
28		Add:

No. , 2014

Intellectual Property Laws Amendment Bill 2014

**Schedule 4** Australia New Zealand Single Economic Market **Part 1** Amendments

2		section to an <i>address</i> includes a reference to an electronic address.
3 4 5		(3) The time specified under subsection (2) must be later than the day on which the regulations are registered under the <i>Legislative Instruments Act</i> 2003.
6 7 8		(4) For the purposes of this section, the question of whether an electronic address is in Australia is to be determined in accordance with the regulations.
9 10 11		(5) For the purposes of this section, the question of whether an electronic address is in New Zealand is to be determined in accordance with the regulations.
12	33	After paragraph 223(1)(b)
13		Insert:
14		(ba) a New Zealand delegate; or
15	34	After subsection 223(1)
16		Insert:
17 18		(1A) For the purposes of subsection (1), it is immaterial whether a relevant act took place, or is to take place, in New Zealand.
19 20		(1B) For the purposes of subsection (1), it is immaterial whether an error or omission took place in New Zealand.
21	35	After subsection 224(3)
22		Insert:
23		(3A) For the purposes of this section, it is immaterial whether a decision
24		was made in New Zealand.
25	36	Section 227 (heading)
26		Repeal the heading, substitute:

Australia New Zealand Single Economic Market Schedule 4
Amendments Part 1

1	227 Fees payable under this Act
2	37 At the end of section 227
3	Add:
4	(6) For the purposes of this Act, if:
5 6	(a) a fee is declared by the regulations to be a fee to which this subsection applies; and
7	(b) the fee is paid to:
8	(i) the New Zealand Commissioner of Patents; or
9	(ii) a New Zealand Assistant Commissioner of Patents; or
10 11	(iii) a person who, under a law of New Zealand, is a delegate of the New Zealand Commissioner of Patents; and
12	(c) the New Zealand Commissioner of Patents, the New Zealand
13	Assistant Commissioner of Patents, or the delegate, as the
14	case may be, is authorised to receive the fee on behalf of the
15	Commonwealth; and
16	(d) the fee is paid in New Zealand currency;
17	then:
18	(e) the liability to pay the fee is discharged; and
19 20	(f) this Act has effect as if the fee had been paid in accordance with the regulations.
21	(7) For the purposes of subsection (6), the amount of the fee in New
22 23	Zealand currency is to be ascertained in accordance with the regulations.
24	38 After section 227
25	Insert:
26	227AA Receipt of fees payable under New Zealand law
27	The regulations may make provision for and in relation to
28	authorising:
29	(a) the Commissioner; or
30	(b) a Deputy Commissioner; or
31	(c) an employee;

No. , 2014

Intellectual Property Laws Amendment Bill 2014

**Schedule 4** Australia New Zealand Single Economic Market **Part 1** Amendments

	to receive, on behalf of New Zealand, a specified fee payable under a specified law of New Zealand that relates to patents for
	inventions, so long as:
	(d) the fee is paid in Australian currency; and
	(e) the amount of the fee in Australian currency is ascertained in accordance with the regulations.
227A	B Application of administrative law regime to decisions made in New Zealand
	Judicial review
	(1) For the purposes of the application of the <i>Administrative Decisions</i> ( <i>Judicial Review</i> ) <i>Act 1977</i> to a decision under this Act, it is immaterial whether the decision was made in New Zealand.
	Note: See also the <i>Trans-Tasman Proceedings Act 2010</i> .
	(2) For the purposes of subsection (1), <i>decision</i> has the same meaning as in the <i>Administrative Decisions (Judicial Review) Act 1977</i> .
	Merits review
	(3) For the purposes of the application of the <i>Administrative Appeals Tribunal Act 1975</i> to a decision under this Act, it is immaterial whether the decision was made in New Zealand.
	Note: See also the <i>Trans-Tasman Proceedings Act 2010</i> .
	(4) For the purposes of subsection (3), <i>decision</i> has the same meaning as in the <i>Administrative Appeals Tribunal Act 1975</i> .
39 S	Section 227A (heading)
	Repeal the heading, substitute:
227A	Trans-Tasman IP Attorneys Board
40 S	Subsection 227A(1)
	Repeal the subsection, substitute:
	(1) The body known immediately before the commencement of this subsection as the Professional Standards Board for Patent and

Intellectual Property Laws Amendment Bill 2014

No. , 2014

Australia New Zealand Single Economic Market Schedule 4
Amendments Part 1

2			Pasman IP Attorneys Board.
3 4		Note 1:	In this Act, <i>Board</i> means the Trans-Tasman IP Attorneys Board—see Schedule 1.
5		Note 2:	See also section 25B of the Acts Interpretation Act 1901.
6	41	Subsection 2	227A(2)
7 8		Omit "Profe".	ssional Standards Board" (wherever occurring), substitute
9	42	After subsec	ction 227A(2)
10		Insert:	
11		Membe	rship of the Board
12			ard consists of the following members:
13		` '	Chair;
14			e Director-General of IP Australia;
15		` '	e New Zealand Commissioner of Patents;
16			least 2 members nominated by the New Zealand Patents
17 18			linister to represent the New Zealand patent attorney rofession;
19		_	least 2 other members.
20		(2B) The total	al number of members of the Board must not exceed 10.
21		Appoint	tment of members of the Board
22		(2C) Each m	ember of the Board mentioned in paragraph (2A)(a), (d) or
23		(e) is to	be appointed by the Minister by written instrument.
24		Note:	For reappointment, see the Acts Interpretation Act 1901.
25		(2D) A perso	on is not eligible for appointment as a member of the Board
26			ned in paragraph (2A)(a), (d) or (e) unless the Minister is
27		satisfied	d that the person has:
28		(a) su	ibstantial experience or knowledge; and
29			gnificant standing;
30		in at lea	st one of the following fields:
31		(c) A	ustralian patent attorney practice;

No. , 2014

Intellectual Property Laws Amendment Bill 2014

**Schedule 4** Australia New Zealand Single Economic Market **Part 1** Amendments

1	(d) New Zealand patent attorney practice;
2	(e) Australian trade mark attorney practice;
3	(f) the regulation of persons engaged in a prescribed occupation;
4	(g) public administration;
5	(h) academia.
6	(2E) A member of the Board holds office on a part-time basis.
7	Period of appointment for members of the Board
8	(2F) A member of the Board mentioned in paragraph (2A)(a), (d) or (e)
9 10	holds office for the period specified in the instrument of appointment. The period must not exceed:
	**
11 12	(a) in the case of the member mentioned in paragraph (2A)(a)—3 years; or
13	(b) otherwise—5 years.
13	•
14	Note: For reappointment, see the Acts Interpretation Act 1901.
15	Appointment of deputy of Director-General of IP Australia
16	(2G) The Director-General of IP Australia may appoint an APS
17	employee to be his or her deputy for the purpose of attendance at
18	one or more specified meetings of the Board.
19	(2H) If:
20	(a) a person is the deputy of the Director-General of IP Australia
21	for the purpose of attendance at a particular meeting of the
22	Board; and
23	(b) the Director-General of IP Australia is absent from the
24	meeting;
25	the person is entitled to attend the meeting and, when so attending,
26	is taken to be a member of the Board.
27	(2J) A deputy of the Director-General of IP Australia is not entitled to
28	any remuneration or allowances for attending a meeting of the
29	Board (other than remuneration or allowances payable to the
30	deputy in his or her capacity as an APS employee).

Australia New Zealand Single Economic Market Schedule 4
Amendments Part 1

	Appointment of aeputy of New Zealana Commissioner of Patents
	(2K) The New Zealand Commissioner of Patents may appoint a New
	Zealand patents official to be his or her deputy for the purpose of
	attendance at one or more specified meetings of the Board.
	(2L) If:
	(a) a person is the deputy of the New Zealand Commissioner of
	Patents for the purpose of attendance at a particular meeting of the Board; and
	(b) the New Zealand Commissioner of Patents is absent from the meeting;
	the person is entitled to attend the meeting and, when so attending,
	is taken to be a member of the Board.
	(2M) A deputy of the New Zealand Commissioner of Patents is not
	entitled to any remuneration or allowances for attending a meeting
	of the Board (other than remuneration or allowances payable to the deputy in his or her capacity as a New Zealand patents official).
	deputy in his of her capacity as a New Zearand patents official).
43	Paragraph 227A(3)(a)
	Repeal the paragraph, substitute:
	(a) the terms and conditions on which members of the Board
	mentioned in paragraph (2A)(a), (d) or (e) hold office; and
	(aa) the manner in which members of the Board mentioned in paragraph (2A)(a), (d) or (e) may resign their appointments; and
	(ab) the termination of the appointment of members of the Board
	mentioned in paragraph (2A)(a), (d) or (e); and
44	Paragraphs 227A(3)(b) and (c)
	Omit "Professional Standards Board", substitute "Board".
45	Subsections 227A(4) and (5)
	Omit "Professional Standards Board", substitute "Board".
46	At the end of section 227A
	Add:

No. , 2014

Intellectual Property Laws Amendment Bill 2014

Schedule 4 Australia New Zealand Single Economic Market Part 1 Amendments

47	Subparagraph 228(2)(r)(ia)
	Omit "Professional Standards Board", substitute "Board".
48	After subsection 228(4)
	Insert:
	(4A) If the regulations confer a function on a person or body, the regulations may provide that the function may be performed in Australia or New Zealand.
	(4B) If the regulations confer a power on a person or body, the regulations may provide that the power may be exercised in Australia or New Zealand.
	(4C) If the regulations provide that application may be made to the Administrative Appeals Tribunal for review of a decision, the regulations may provide that it is immaterial whether the decision was made in New Zealand.
	(4D) The regulations may provide that it is immaterial whether an act or omission mentioned in the regulations took place in New Zealand.
	(4E) The regulations may provide that it is immaterial whether a matter mentioned in the regulations concerns something that took place in New Zealand.
49	Schedule 1
	Insert:
	<b>Board</b> means the Trans-Tasman IP Attorneys Board continued in existence by section 227A.
50	Schedule 1 (definition of <i>company</i> )
	Repeal the definition, substitute:
	company means:
	(a) a company registered under the Corporations Act 2001; or
	(b) a company registered under the Companies Act 1993 of New Zealand.

Australia New Zealand Single Economic Market Schedule 4
Amendments Part 1

51	Schedule 1
	Insert:
	<i>Director-General of IP Australia</i> means the SES employee who holds or performs the duties of the position of Director-General of IP Australia.
52	Schedule 1 (at the end of the definition of file)
	Add:
	Note: See also section 214.
53	Schedule 1
	Insert:
	New Zealand Assistant Commissioner of Patents means a person
	who holds or performs the duties of an office or position of
	Assistant Commissioner of Patents under or in accordance with a
	law of New Zealand.
54	Schedule 1
	Insert:
	New Zealand Commissioner of Patents means the person who
	holds or performs the duties of the office or position of
	Commissioner of Patents under or in accordance with a law of New Zealand.
55	Schedule 1
	Insert:
	New Zealand delegate means a New Zealand patents official who
	is a delegate under subsection 209(1A).
56	Schedule 1
	Insert:
	New Zealand Patents Minister means the Minister of New Zealand when
	Zealand who:  (a) under the authority of a warrant; or
	(a) under the authority of a warrant; or (b) with the authority of the Prime Minister of New Zealand;
	(b) with the authority of the Fifthe Millister of New Zealand,

No. , 2014

Intellectual Property Laws Amendment Bill 2014

**Schedule 4** Australia New Zealand Single Economic Market **Part 1** Amendments

Schedule 1 Insert:  New Zealand patents official means a person:  (a) who is an employee in any part of the State services of New
<ul><li>New Zealand patents official means a person:</li><li>(a) who is an employee in any part of the State services of New</li></ul>
(a) who is an employee in any part of the State services of New
Zealand; and
(b) whose functions or duties relate to the administration of a law of New Zealand relating to patents for inventions.
Schedule 1 (definition of <i>Professional Standards Board</i> )
Repeal the definition.
Schedule 1
Insert:
Registrar of Companies of New Zealand means the person who
holds or performs the duties of the office or position of Registrar of Companies under or in accordance with the Companies Act 1993 of New Zealand.
ant Breeder's Rights Act 1994
Subsection 3(1)
Insert:
address has a meaning affected by subsection (2).
Subsection 3(2)
Repeal the subsection, substitute:
Electronic address
(2) After the time specified in the regulations, a reference in this Act to an <i>address</i> includes a reference to an electronic address.

Intellectual Property Laws Amendment Bill 2014

Australia New Zealand Single Economic Market **Schedule 4**Amendments **Part 1** 

1 2 3		on which the regulations are registered under the <i>Legislative Instruments Act 2003</i> .
4 5		(4) Subsection (2) of this section does not apply to the following references to an <i>address</i> :
6 7		<ul><li>(a) a reference in subsection 26(2);</li><li>(b) the first reference in subsection 26(3).</li></ul>
8 9 10		(5) For the purposes of this Act, the question of whether an electronic address is in Australia is to be determined in accordance with the regulations.
11 12 13		(6) For the purposes of this Act, the question of whether an electronic address is in New Zealand is to be determined in accordance with the regulations.
14	62	After subsection 19(5)
15		Insert:
16 17		(5A) An address given under paragraph (5)(c) must be an address in Australia or New Zealand.
18	63	Subsection 21(5)
19		After "Australia", insert "or New Zealand".
20	64	Subsection 26(3)
21		After "overseas", insert "in a country other than New Zealand".
22	65	Subsection 26(3)
23		After "Australia" (first occurring), insert "or New Zealand".
24	66	Subsection 26(3)
25 26		Omit "a postal address in Australia", substitute "an address in Australia or New Zealand".
27	67	Subsection 31(3)
28		After "Australia", insert "or New Zealand".

No. , 2014

Intellectual Property Laws Amendment Bill 2014

**Schedule 4** Australia New Zealand Single Economic Market **Part 1** Amendments

1	68	Section 73
2		Repeal the section, substitute:
3	73	Service of documents
4		If:
5 6		(a) this Act provides for a document to be served on, or given or sent to, a person; and
7 8		(b) the person has given the Secretary or the Registrar an address in Australia or New Zealand for service;
9 10		the document may be served on, or given or sent to, the person by a prescribed means to that address.
11	Tre	ade Marks Act 1995
12	69	Readers guide (list of terms defined in section 6)
13		Insert the following term in its appropriate alphabetical position:
14		"Board".
15	70	Readers guide (list of terms defined in section 6)
16		Omit "Professional Standards Board".
17	71	Subsection 6(1)
18		Insert:
19		Board has the same meaning as in the Patents Act 1990.
20	72	Subsection 6(1) (definition of <i>Professional Standards</i>
21		Board)
22		Repeal the definition.
23	73	At the end of subsection 215(5)
24		Add "or New Zealand".
25	74	Paragraph 215(6)(a)
26		Repeal the paragraph, substitute:

42 Intellectual Property Laws Amendment Bill 2014

Australia New Zealand Single Economic Market **Schedule 4**Amendments **Part 1** 

	(a) if the person has an address for service—the document may be served on, or given or sent to, the person by a prescribed means to that address; or
75	Paragraph 215(6)(b)
	After "Australia" (first occurring), insert "or New Zealand".
76	Paragraph 215(6)(b)
	Omit "post", substitute "a prescribed means".
77	Paragraph 215(6)(b)
	After "Australia" (second occurring), insert "or New Zealand".
78	At the end of section 215
	Add:
	(8) After the time specified in the regulations, a reference in this
	section to an <i>address</i> includes a reference to an electronic address.
	(9) The time specified under subsection (8) must be later than the day on which the regulations are registered under the <i>Legislative Instruments Act 2003</i> .
	(10) For the purposes of this section, the question of whether an electronic address is in Australia is to be determined in accordance with the regulations.
	(11) For the purposes of this section, the question of whether an electronic address is in New Zealand is to be determined in accordance with the regulations.
79	Subsection 228A(5)
	Omit "the Professional Standards Board", substitute "the Board".
80	Subsection 228A(5) (note)
	Omit "Professional Standards Board", substitute "Board".
81	Subparagraph 231(2)(ha)(ia)
	Omit "Professional Standards Board", substitute "Board".

No. , 2014

43

Intellectual Property Laws Amendment Bill 2014

**Schedule 4** Australia New Zealand Single Economic Market **Part 2** Transitional provisions

#### Part 2—Transitional provisions

2	02	rransitional—registration as a patent attorney
3	(1)	The Designated Manager must:
4 5		(a) register as a patent attorney an individual who, immediately before the commencement of this item:
6 7		(i) was registered as a patent attorney under a law of New Zealand; and
8 9		(ii) was not a registered patent attorney (within the meaning of the <i>Patents Act 1990</i> ); and
10 11		(b) do so as soon as practicable after the commencement of this item.
12 13	(2)	The registration is to consist of entering the individual's name in the Register of Patent Attorneys.
14 15	(3)	For the purposes of the <i>Patents Act 1990</i> , the registration is taken to be under that Act.
16 17	83	Transitional—qualification for registration as a patent attorney
18 19 20 21	(1)	A qualification specified in, or ascertained in accordance with, regulations made for the purposes of paragraph 198(4)(b) of the <i>Patents Act 1990</i> may consist of passing examinations conducted in New Zealand, so long as:
22 23 24		<ul><li>(a) the examinations are specified in those regulations; and</li><li>(b) at least one of those examinations was passed before the commencement of this item; and</li></ul>
25 26		(c) the remaining examinations are passed before the end of the 4-year period beginning at the commencement of this item.
27 28 29 30	(2)	Regulations authorised by subitem (1) do not apply to examinations passed by an individual unless the individual applies for registration as a patent attorney under section 198 of the <i>Patents Act 1990</i> within 6 months after the completion of the last of those examinations.
31	(3)	Subitem (1) does not limit paragraph 198(4)(b) of the <i>Patents Act 1990</i> .

Intellectual Property Laws Amendment Bill 2014

44

Australia New Zealand Single Economic Market **Schedule 4**Transitional provisions **Part 2** 

1	84	ransitional—conduct of patent attorneys
2 3 4	(1)	Grounds prescribed for the purposes of section 199 of the <i>Patents Act</i> 1990 may relate to conduct that took place in New Zealand before the commencement of this item.
5	(2)	Subitem (1) does not limit section 199 of the Patents Act 1990.
6	85	Transitional—registration as a trade marks attorney
7	(1)	If:
8 9		(a) immediately before the commencement of this item, an individual:
10 11		(i) was registered as a patent attorney under a law of New Zealand; and
12 13		(ii) was not a registered trade marks attorney (within the meaning of the <i>Trade Marks Act 1995</i> ); and
14 15 16		(b) within 12 months after the commencement of this item, the individual applies to the Designated Manager to be registered as a trade marks attorney; and
17		(c) the application is in accordance with the regulations; and
18 19 20 21 22		(d) the individual satisfies the Designated Manager, in accordance with the regulations, that the individual's level of competency in trade marks law and practice is sufficient to warrant the individual becoming a registered trade marks attorney; and
23 24 25		<ul><li>(e) the individual has not been convicted of a prescribed offence during the 5-year period ending when the application was made; and</li></ul>
26 27		<ul><li>(f) the individual is not under sentence of imprisonment for a prescribed offence;</li></ul>
28 29		the Designated Manager must register the individual as a trade marks attorney.
30 31	(2)	The registration is to consist of entering the individual's name in the Register of Trade Marks Attorneys.
32 33	(3)	For the purposes of the <i>Trade Marks Act 1995</i> , the registration is taken to be under that Act.

No. , 2014

Intellectual Property Laws Amendment Bill 2014

**Schedule 4** Australia New Zealand Single Economic Market **Part 2** Transitional provisions

1 2	(4)	The Governor-General may make regulations for the purposes of this item.			
3	(5)	It is immaterial whether a matter mentioned in paragraph (1)(d), (e) or (f) concerns something that happened in New Zealand.			
5 6 7	(6)	A reference in this item to <i>conviction</i> of an offence includes a reference to:  (a) the making of an order under section 19B of the <i>Crimes Act</i>			
8 9 10		<ul><li>1914 in relation to the offence; or</li><li>(b) the making of an order under a corresponding provision of a law of:</li></ul>			
11 12		(i) a State; or (ii) a Territory; or			
13 14		(iii) New Zealand; in relation to the offence.			

Intellectual Property Laws Amendment Bill 2014

Other amendments Schedule 5
Document retention Part 1

Schedule 5—Other amendments
Part 1—Document retention
Division 1—Amendments
Designs Act 2003
1 Paragraph 69(3)(b) Omit "design; and", substitute "design.".
2 Paragraph 69(3)(c) Repeal the paragraph.
Patents Act 1990
3 Paragraph 228(2)(u) Repeal the paragraph.
Trade Marks Act 1995
4 Paragraph 231(2)(h) Repeal the paragraph.
Division 2—Application of amendments
5 Application of amendments
The amendments made by this Part apply in relation to material and documents provided or filed before, on or after the commencement of this Part.

No. , 2014

Intellectual Property Laws Amendment Bill 2014

Schedule 5 Other amendments
Part 2 Technical amendments

_	ivision 1—Amendments
P	atents Act 1990
6	Section 24 (heading)
	Repeal the heading, substitute:
24	Validity not affected by making information available in certain circumstances
7	Section 29A (note)
	Repeal the note.
8	At the end of section 29
	Add:
	(6) An applicant is not entitled to ask that any action be taken, or that he or she be allowed to take any action, under this Act in relation to a PCT application unless the following requirements of subsection (5) have been met (if applicable):
	<ul><li>(a) a translation of the application into English has been filed;</li><li>(b) the prescribed documents have been filed;</li></ul>
	(c) the prescribed fees have been paid.
	Note: A failure to comply with subsection (5) may also result in the PCT application lapsing: see paragraph 142(2)(f).
9	Subsection 29B(2)
	Omit "within the prescribed period".
1(	Subsection 29B(6)
	Omit "subsection (1)", substitute "the definition of <i>Convention country</i> in subsection (5)".

Other amendments **Schedule 5** Technical amendments **Part 2** 

1	11	Before subsection 40(2)
2		Insert:
3		Requirements relating to complete specifications
4	12	Before subsection 41(1)
5		Insert:
6		Provisional specifications
7 8		(1A) A specification is taken to comply with subsection 40(1), so far as it requires a description of a micro-organism, if:
9 10 11		(a) the micro-organism is deposited with a prescribed depository institution in accordance with such provisions of the Budapest Treaty as are applicable; and
12		(b) the prescribed circumstances apply.
13		Complete specifications
14	13	Paragraph 43(2A)(b)
15 16		After "discloses", insert ", or a prescribed set of prescribed documents considered together disclose,".
17	14	After subsection 43(2A)
18		Insert:
19 20 21 22		(2B) A prescribed document, or a prescribed set of prescribed documents considered together, is taken to disclose the invention in a claim as mentioned in paragraph (2A)(b) so far as such disclosure requires a description of a micro-organism, if:
23 24 25		<ul><li>(a) the micro-organism is deposited with a prescribed depository institution in accordance with such provisions of the Budapest Treaty as are applicable; and</li><li>(b) the prescribed circumstances apply.</li></ul>
26		
27 28	15	At the end of subparagraph 101E(1)(a)(ix) Add "and".

No. , 2014

Intellectual Property Laws Amendment Bill 2014

Schedule 5 Other amendments
Part 2 Technical amendments

1	16	Paragraph 119(3)(b)			
2		Omit "through any publication or use of the invention".			
3	17	Subsection 178(4)			
4		Omit "subsection (1) or (2)", substitute "this section".			
5	18	Subsection 191A(4)			
6 7 8		Omit "a declaration, or rectify the Register, under this section", substitute "a declaration under subsection (2), or rectify the Register under subsection (3),".			
9	19	Paragraph 224(1)(a)			
10		Omit "or 142(2)(b)".			
11	Div	vision 2—Application of amendments			
12	20	Application of amendments			
13 14 15	(1)	The amendments made by items 6 and 16 apply in relation to information that is made publicly available at or after the time those items commence.			
16 17	(2)	The amendments made by items 7, 8 and 9 apply in relation to applications made at or after the time those items commence.			
18 19	(3)	The amendment made by item 12 applies in relation to provisional applications made at or after the time that item commences.			
20	(4)	The amendments made by items 13 and 14 apply in relation to:			
21		(a) patents for which the complete application is made at or after			
22		the time those items commence; and			
23 24		(b) standard patents for which the application had been made before the time those items commence, if the applicant had			
24 25		not asked for an examination of the patent request and			
26		specification for the application under section 44 of the			
27		Patents Act 1990 before that time; and			
28		(c) innovation patents granted at or after the time those items			
29		commence, if the complete application to which the patent			
30		relates had been made before that time; and			

Other amendments **Schedule 5** Technical amendments **Part 2** 

1 2		(d)	complete patent applications made at or after the time those items commence; and
		( )	
3		(e)	complete applications for standard patents made before the
4			time those items commence, if the applicant had not asked
5			for an examination of the patent request and specification for
6			the application under section 44 of the <i>Patents Act 1990</i>
7			before that time; and
8		(f)	complete applications for innovation patents made before the
9			time those items commence, if a patent had not been granted
0			in relation to the application on or before that time; and
1		(g)	innovation patents granted before the time those items
2		(2)	commence, if:
13			(i) the Commissioner had not decided to examine the
4			complete specification relating to the patent under
15			section 101A of the <i>Patents Act 1990</i> before that time;
16			and
17			(ii) the patentee or any other person had not asked the
8			Commissioner to examine the complete specification
9			relating to the patent under section 101A of the <i>Patents</i>
20			Act 1990 before that time.
21	(5)	The amen	dment made by item 18 applies on and after the day that item
22	(-)		es in relation to patents granted before, on or after that
22		commence	